Jansen L et al. – The adjusted results do not support the hypothesis that beta blocker use is associated with decreased risk of colorectal cancer (CRC). In contrast, the authors found a positive association of long–term beta blocker use and risk of stage IV CRC.
Between 2003 and 2007, information on beta blocker use and potential confounders was collected by personal interviews for 1762 CRC cases and 1708 control individuals from Germany.
The association of CRC risk and beta blocker use and subclasses of beta blockers was estimated by multiple logistic regression.
In addition, site- and stage-specific analyses were performed.
After adjustment for covariates, no association was observed with beta blocker use (odds ratio [OR], 1.05; 95% confidence interval [CI], 0.86-1.29) or with duration of beta blocker use.
Also, the analysis by subclasses of beta blockers (cardioselectivity) and active ingredients (metoprolol, bisoprolol, carvedilol, and atenolol) or by CRC subsite showed no associations.
In stage-specific analyses, long-term beta blocker use (6+years) was associated with a significantly higher risk of stage IV CRC (OR, 2.02; 95% CI, 1.25-3.27).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.